A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis Academic Article uri icon

Overview

MeSH Major

  • Abatacept
  • Giant Cell Arteritis

abstract

  • In patients with GCA, the addition of abatacept to a treatment regimen with prednisone reduced the risk of relapse and was not associated with a higher rate of toxicity compared to prednisone alone.

authors

publication date

  • April 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5378642

Digital Object Identifier (DOI)

  • 10.1002/art.40044

PubMed ID

  • 28133925

Additional Document Info

start page

  • 837

end page

  • 845

volume

  • 69

number

  • 4